PIPELINE

Investigational Products

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Alcoholic hepatitis (AH)

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Psoriasis

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Nonalcoholic steatohepatitis (NASH)

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Postoperative pain

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Human immunodeficiency virus (HIV)

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Attention-deficit hyperactivity disorder (ADHD)

*Phase III study conducted in Taiwan. Approved in Taiwan as Methydur Sustained Release Capsules. Not approved in any other country.